Form 4: Black Diamond Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Shannon Campbell acquired 30,550 stock options in Black Diamond Therapeutics, Inc. on June 6, 2024.
Summary
- On June 6, 2024, Shannon Campbell, a director of Black Diamond Therapeutics, Inc. (BDTX), acquired 30,550 stock options.
- The exercise price of these options is $4.65.
- The options vest fully on the earlier of June 6, 2025, or the Issuer's next annual meeting of stockholders, contingent upon continued service.
- The options expire on June 5, 2034.
Sentiment
Score: 6
Explanation: The document itself is neutral, simply reporting a transaction. The acquisition of stock options by a director is generally viewed as a mildly positive signal, suggesting confidence in the company's future.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The vesting of the options is contingent upon the director's continued service, suggesting an expectation of ongoing involvement with the company.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into insider transactions.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of transaction: Director Shannon Campbell acquired stock options. |
| 06/06/2025 | Earliest vesting date for the stock options, contingent on continued service. |
| 06/05/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.